Brisk first quarter trading has given UK drugmaker AstraZeneca (LSE: AZN) a better-than-expected revenue figure of $5.5 billion for the first three months of 2019, up 6% from the same period last year.
Following Generally Accepted Accounting Principles (GAAP), AstraZeneca booked a profit of $1.1 billion, giving an earnings per share (EPS) figure of $0.47, a 75% increase on the first quarter of 2018.
The firm, which announced at the start of the year it had finally returned to growth, has reaped rewards from a continued focus on oncology and emerging markets, particularly China.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze